RecruitingNot ApplicableNCT06583876

Bio Refine for Functional Mitral Regurgitation - a Safety & Feasibility Study


Sponsor

Bio Refine Ltd.

Enrollment

15 participants

Start Date

Jun 3, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the safety and feasibility of the Bio Refine Coriofix System and determine if it might help in treatment of functional mitral regurgitation. The study will include patients with symptomatic secondary mitral regurgitation in whom mitral surgery cannot and/or will not be offered as a treatment option (the risk is prohibitive). Potential patients will be screened to confirm that all inclusion/exclusion criteria are met, with final eligibility confirmation on day of procedure. All enrolled subjects who went through the procedure will be followed during the procedure to hospital discharge. Additional follow up time points are scheduled at 30 days, 6 months and 12 months post procedure.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Coriofix System for people with functional mitral regurgitation. The study is currently recruiting participants at 4 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECoriofix System

Treatment of functional mitral regurgitation by reducing the mitral valve annular area through ablation of the posterior annulus.


Locations(4)

Gottsegen National Cardiovascular Center

Budapest, Hungary

Rabin Medical Center

Petah Tikva, Israel

Institute for Cardiovascular Diseases "Dedinje"

Belgrade, Serbia

University Clinical Center Kragujevac

Kragujevac, Serbia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06583876


Related Trials